Related Experiment Videos
Combined therapy in children and adolescents with IgA nephropathy
K Murakami1, K Yoshioka, N Akano
1Department of Pediatrics, Kinki University School of Medicine, Osaka, Japan.
Insights
This study found that a 6-month combination therapy for IgA nephropathy in children temporarily reduced proteinuria but offered limited long-term renal benefit. Warfarin did not enhance treatment outcomes.
Area of Science:
- Pediatric Nephrology
- Immunology
- Pharmacology
Background:
- IgA nephropathy (IgAN) is a common cause of progressive renal failure in children.
- Children with IgAN and features of progressive renal failure require effective therapeutic strategies.
- Assessing long-term renal outcomes of combination therapy in pediatric IgAN is crucial.
Purpose of the Study:
- To evaluate the long-term renal outcome of a 6-month combination therapy in children and adolescents with IgA nephropathy.
- To compare the efficacy of a combination therapy with and without warfarin.
- To assess the impact of therapy on proteinuria, creatinine clearance, and renal biopsy findings.
Main Methods:
- Retrospective evaluation of 38 children and adolescents with IgA nephropathy.
- Group A (n=17) received prednisolone, cyclophosphamide, and dipyridamole.
- Group B (n=21) received the same regimen plus warfarin, followed for >2 years.
Main Results:
- Both groups showed significant short-term reduction in proteinuria, sustained for up to 6 years.
- Creatinine clearance remained stable for 5-6 years, with 4 patients progressing to end-stage renal failure.
- Renal biopsies showed improved activity scores but unchanged chronicity scores.
Conclusions:
- The combination therapy provided temporary renal benefit in pediatric IgAN patients.
- Long-term efficacy was limited, with no substantiated additive benefit from warfarin.
- Further research is needed to identify more effective treatments for progressive IgAN in children.
Abstract:
We retrospectively evaluated renal outcome in a total of 38 children and adolescents with IgA nephropathy who were selected for 6-month therapy for clinical (proteinuria > 1 g/m2/24 hour) and pathologic (mesangial proliferation, crescent formation, and tubulo-interstitial changes) features suggestive of progressive renal failure. Seventeen patients (group A) were treated with a combination of prednisolone, cyclophosphamide and dipyridamole, and the remaining patients (21; group B) were treated with the same drugs plus warfarin. All the patients were followed-up for more than 2 years (range 2-10 years, mean 4.8). In both groups, the mean urinary protein excretion value was significantly reduced after the therapy, compared with that at entry into the therapy. The significant reduction continued for up to 6 years in group A and up to 5 years in group B. Creatinine clearance was stable until 5-6 years after the trial in both groups, but 4 patients progressed to end-stage renal failure after that period. Post-therapy biopsy was performed in 14 patients, and was compared with the pre-therapy biopsy. The activity score had improved in both groups, but the chronicity score did not. These results indicate that there was a temporary effect and limited benefit with this treatment of combined drugs for children and adolescents with IgA nephropathy. The additive effect of warfarin was not substantiated.